Innate Pharma doses first patient in relapsed/refractory multiple myeloma trial
Innate Pharma has announced that the first patient has been dosed in its Sanofi-sponsored phase 1/2 clinical trial, which aims to assess SAR’514/IPH6401 for the treatment of relapsed/refractory Multiple Myeloma (RRMM) and relapsed/refractory light-chain Amyloidosis (RRLCA).
The dose escalation and expansion study aims to assess the safety, pharmacokinetics and preliminary efficacy of the drug as a monotherapy for patients with RRMM or RRLCA. The initiation of the trial has triggered a milestone payment from Sanofi to Innate, as part of a previously announced research collaboration between the two companies.
Joyson Karakunnel, MD MSc FACP, chief medical officer at Innate Pharma, commented: “We are pleased to see a second molecule from our ANKET platform reaching the clinic. In addition to the targeting of the tumour antigen BCMA, SAR’514/IPH6401 co-engages the two activating receptors NKp46 and CD16 to leverage the advantages of harnessing NK cell effector functions against cancer cells and thus has the potential to be a new innovative option for patients living with RRMM or RRLCA.”
Peter Adamson, MD, global development head of Oncology at Sanofi, added: “We are excited to see our collaboration with Innate Pharma continue to move forward, leveraging scientific advances in our understanding of the potential of NK cells to impact cancer. Our first patient dosed with SAR’514/IPH6401 is indeed welcome news. We look forward to data as it emerges, with the goal of improving the outcome for patients with RRMM or RRLCA.”
Acurx Pharmaceuticals announces positive data from phase 2b trial for C. difficile infection treatment
Acurx Pharmaceuticals has announced that it has discontinued its phase 2b clinical trial of its …
NMD Pharma has announced that the first patient has been dosed in its phase 2 …